Rights and permissions
About this article
Cite this article
Ruxolitinib has a positive impact on QOL in myelofibrosis patients. Pharmacoecon. Outcomes News 644, 9 (2012). https://doi.org/10.2165/00151234-201206440-00024
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-201206440-00024